Controlled substance scheduling proposed for UCB's anti-epileptic Vimpat
This article was originally published in Scrip
Executive Summary
UCB's anti-epileptic Vimpat (lacosamide) should be classified as a schedule V controlled substance, the US Drug Enforcement Administration (DEA) said in a proposed rule. Vimpat has a lower potential for abuse, and more limited physical or psychological dependence, relative to drugs in the more restrictive schedule IV category, the agency said.